Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2012 May;91(5):846-55. doi: 10.1038/clpt.2011.313.

PMID:
22472994
2.

Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT.

Drug Metab Dispos. 2011 Oct;39(10):1977-86. doi: 10.1124/dmd.111.040931. Epub 2011 Jul 21.

PMID:
21778352
3.

Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2011 Apr;89(4):579-86. doi: 10.1038/clpt.2010.358. Epub 2011 Mar 2.

PMID:
21368757
4.

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.

Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ.

Drug Metab Dispos. 2009 Dec;37(12):2359-66. doi: 10.1124/dmd.109.029728. Epub 2009 Sep 22.

PMID:
19773535

Supplemental Content

Loading ...
Support Center